Skip to main content

Table 1 Participant characteristics (N = 203)

From: Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?

  Overall population With symptom cluster Without symptom cluster
Mean age (SD) 60.5 (8.5) yr 60.1 (9.4) yr 60.6 (8.3) yr
Body mass index (kg/m2)    
 Normal weight (18.5–24.9) 83 (41.1 %) 9 (26.5 %) 74 (44 %)
 Overweight (25–29.9) 59 (29.2 %) 12 (35.3 %) 47 (28 %)
 Obese (>30) 60 (29.7 %) 13 (38.2 %) 47 (28 %)
Race    
 White 163 (80.7 %) 26 (76.5 %) 137 (81.5 %)
 Non-white 39 (19.3 %) 8 (23.5 %) 31 (18.5 %)
Education    
 High school or less 46 (22.8 %) 8 (23.5 %) 38 (22.6 %)
 College 93 (46 %) 20 (58.8 %) 73 (43.5 %)
 Graduate/professional 63 (31.2 %) 6 (17.7 %) 57 (33.9 %)
Years since LMP    
 <5 yr 41 (21.5 %) 13 (40.6 %) 80 (50.3 %)
 5–10 yr 57 (29.8 %) 10 (31.3 %) 47 (29.6 %)
 >10 yr 93 (48.7 %) 9 (28.1 %) 32 (20.1 %)
Cancer stage    
 Stage 0/I 94 (47 %) 13 (38.2 %) 81 (48.8 %)
 Stage II 81 (40.5 %) 16 (47.1 %) 65 (39.2 %)
 Stage III 25 (12.5 %) 5 (14.7 %) 20 (12 %)
AI taken    
 Anastrozole 148 (74.4 %) 27 (79.4 %) 121 (73.3 %)
 Exemestane 20 (10 %) 2 (5.9 %) 18 (10.9 %)
 Letrozole 31 (15.6 %) 5 (14.7 %) 26 (15.8 %)
Years on AI    
 <1 yr 54 (26.7 %) 11 (32.4 %) 43 (25.6 %)
 1–3 yr 85 (42.1 %) 12 (35.3 %) 73 (43.5 %)
 >3 yr 63 (31.2 %) 11 (32.3 %) 52 (30.9 %)
Chemotherapy history    
 None 77 (38.3 %) 14 (41.2 %) 63 (37.7 %)
 Regimen with a taxane 78 (38.8 %) 10 (29.4 %) 36 (21.6 %)
 Regimen without a taxane 46 (22.9 %) 10 (29.4 %) 68 (40.7 %)
NSAID use in last 7 days    
 Yes 61 (30.3 %) 17 (50 %) 44 (26.3 %)
 No 138 (68.7 %) 17 (50 %) 121 (72.5 %)
 Don’t know 2 (1 %) 0 (0 %) 2 (1.2 %)
  1. AI aromatase inhibitor, LMP last menstrual period, NSAID non-steroidal anti-inflammatory drug, SD standard deviation
  2. Symptom cluster refers to comorbid arthralgia, fatigue, and insomnia